Survey reveals generics penetration in Peru



According to a recent poll by newspaper El Comercio and consulting firm Ipsos, 90% of people in Peru have used generic drugs while 9% never consumed them. Within users of generics, 82% reported benefiting from the treatment, while 18% did not experience any improvement.

Reference:

Related news
China-based Shanghai Shyndec Pharmaceutical Co., Ltd, (600420.SH) announced that its generic version of micafungin won a market approval nod from the National Medical Products Administration (NMPA).
According to GBI analysis, Chile’s Institute of Public Health (ISP) last week cleared Argentine laboratory Monte Verde’s Vilzer (vildagliptin), a first market generic entrant against Novartis’s antidiabetic Galvus/Jalra.
GBI’s key takeaways: Mexico has released its National Compendium of Health Products (CNIS), an updated EDL for the public health system.
Chile's National Economic Prosecutor (FNE) last week published a preliminary report on the biopharmaceutical industry, presenting a set of measures to reduce medicine prices in the country.
The Medicine Price Index 2019 study published last week by digital healthcare provider Medbelle compares the online prices of 13 medicines for a variety of common conditions in 50 markets across the globe, including Argentina, Brazil, Chile, Colombia, and Mexico​.
Recent news
Chile’s Ministry of Health (MINSAL) this week announced measures against gender and age inequalities regarding Welfare Health Institutions (ISAPREs) fees.
Brazil-based Biolab, the leading seller of cardiology medicines in the Brazilian market, has signed an agreement with France-based Quantum Genomics to partner on the development, production, and commercialization in Latin America of a novel treatment for hypertension.
According to preliminary data from Mexico’s 2018 National Health and Nutrition Survey (ENSANUT), chronic diseases have continued to increase in the country since the previous survey in 2012.
Shandong province is set to scrap mark-ups on medical consumables at public medical institutions, according to a document released by the province.
US-based AbbVie’s Bruton’s tyrosine kinase (BTK) inhibitor ABBV-105 and Janus kinase 1 (JAK1) inhibitor upadacitinib (trade name: Rinvoq) have both won clinical trial approvals from the Center for Drug Evaluation (CDE).
China’s national drug use monitoring platform, online since November 25, now covers a network of 8,840 medical institutions and is handling an average 600,000 person visits daily, according to the National Healthcare Commission (NHC).
US-based biotech Amgen (Nasdaq.AMGN) trumpeted a new indication approval for its PCSK9 inhibitor Repatha (evolocumab) in China.
Analytics Snapshot


Analytics Snapshot